EP1624758A4 - HEMOPOETIC STEM CELLS AND METHOD FOR THE TREATMENT OF EYE-RELATED VASCULAR DISEASES USING THESE STEM CELLS - Google Patents

HEMOPOETIC STEM CELLS AND METHOD FOR THE TREATMENT OF EYE-RELATED VASCULAR DISEASES USING THESE STEM CELLS

Info

Publication number
EP1624758A4
EP1624758A4 EP04760595A EP04760595A EP1624758A4 EP 1624758 A4 EP1624758 A4 EP 1624758A4 EP 04760595 A EP04760595 A EP 04760595A EP 04760595 A EP04760595 A EP 04760595A EP 1624758 A4 EP1624758 A4 EP 1624758A4
Authority
EP
European Patent Office
Prior art keywords
lin
isolated
monocytes
hscs
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04760595A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1624758A2 (en
Inventor
Martin Friedlander
Atsushi Otani
Karen Dasilva
Stacey Hanekamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/628,783 external-priority patent/US7153501B2/en
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Priority to EP05025978A priority Critical patent/EP1754783A1/en
Publication of EP1624758A2 publication Critical patent/EP1624758A2/en
Publication of EP1624758A4 publication Critical patent/EP1624758A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP04760595A 2003-05-02 2004-04-28 HEMOPOETIC STEM CELLS AND METHOD FOR THE TREATMENT OF EYE-RELATED VASCULAR DISEASES USING THESE STEM CELLS Ceased EP1624758A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05025978A EP1754783A1 (en) 2003-05-02 2004-04-28 Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46705103P 2003-05-02 2003-05-02
US10/628,783 US7153501B2 (en) 2002-07-25 2003-07-25 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
PCT/US2004/012989 WO2004098499A2 (en) 2002-07-25 2004-04-28 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP05025978A Division EP1754783A1 (en) 2003-05-02 2004-04-28 Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Publications (2)

Publication Number Publication Date
EP1624758A2 EP1624758A2 (en) 2006-02-15
EP1624758A4 true EP1624758A4 (en) 2007-03-07

Family

ID=36908146

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04760595A Ceased EP1624758A4 (en) 2003-05-02 2004-04-28 HEMOPOETIC STEM CELLS AND METHOD FOR THE TREATMENT OF EYE-RELATED VASCULAR DISEASES USING THESE STEM CELLS
EP05025978A Ceased EP1754783A1 (en) 2003-05-02 2004-04-28 Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05025978A Ceased EP1754783A1 (en) 2003-05-02 2004-04-28 Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Country Status (10)

Country Link
EP (2) EP1624758A4 (enExample)
JP (2) JP4714682B2 (enExample)
KR (3) KR101169261B1 (enExample)
CN (2) CN1831119B (enExample)
AU (2) AU2004237749B2 (enExample)
BR (1) BRPI0409861A (enExample)
CA (2) CA2524063C (enExample)
MX (2) MXPA05011750A (enExample)
RU (2) RU2345780C2 (enExample)
ZA (2) ZA200509752B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554662A1 (en) * 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
CN110777124A (zh) 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
RU2495650C1 (ru) * 2012-02-29 2013-10-20 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Трехкомпонентный комплекс для клеточной терапии в офтальмологии
RU2485922C1 (ru) * 2012-03-28 2013-06-27 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения "сухой" формы возрастной макулярной дегенерации
CN107043699B (zh) * 2017-04-25 2023-04-07 徐子雁 一种低能量激光诱导间充质干细胞血管化的试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098521A1 (en) * 2000-10-18 2002-07-25 Dominique Bonnet Method and marker for the isolation of human multipotent hematopoietic stem cells
WO2004010959A2 (en) * 2002-07-25 2004-02-05 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098521A1 (en) * 2000-10-18 2002-07-25 Dominique Bonnet Method and marker for the isolation of human multipotent hematopoietic stem cells
WO2004010959A2 (en) * 2002-07-25 2004-02-05 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GALLACHER LISA ET AL: "Isolation and characterization of human CD34-Lin- and CD34+Lin- hematopoietic stem cells using cell surface markers AC133 and CD7", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 95, no. 9, 1 May 2000 (2000-05-01), pages 2813 - 2820, XP002303837, ISSN: 0006-4971 *
INTERNET CITATION: "StemSepTM Human Primitive Progenitor Enrichment Kit", Retrieved from the Internet <URL:http://www.stemcell.com/product_catalog/product_catalog_index.aspx?print=1&id=519&type=catalog_item> [retrieved on 20100427] *
OTANI ATSUSHI ET AL: "Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells.", THE JOURNAL OF CLINICAL INVESTIGATION. SEP 2004, vol. 114, no. 6, September 2004 (2004-09-01), pages 765 - 774, XP002413476, ISSN: 0021-9738 *
WATANABE M ET AL: "Intravitreal injections of neurotrophic factors and forskolin enhance survival and axonal regeneration of axotomized beta ganglion cells in cat retina.", NEUROSCIENCE. 2003, vol. 116, no. 3, 2003, pages 733 - 742, XP002413475, ISSN: 0306-4522 *
YIN A H ET AL: "AC133, a novel marker for human hematopoietic stem and progenitor cells.", BLOOD. 15 DEC 1997, vol. 90, no. 12, 15 December 1997 (1997-12-15), pages 5002 - 5012, XP002264586, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
EP1624758A2 (en) 2006-02-15
AU2005239702A1 (en) 2005-12-22
KR20060056420A (ko) 2006-05-24
JP2006166918A (ja) 2006-06-29
CN1816281A (zh) 2006-08-09
CA2524063A1 (en) 2004-11-18
CN100439493C (zh) 2008-12-03
EP1754783A1 (en) 2007-02-21
RU2389497C2 (ru) 2010-05-20
AU2005239702B2 (en) 2010-03-04
JP4714580B2 (ja) 2011-06-29
JP4714682B2 (ja) 2011-06-29
CA2524063C (en) 2015-02-17
CA2526670C (en) 2011-06-14
ZA200509756B (en) 2006-10-25
BRPI0409861A (pt) 2006-05-16
KR20120034251A (ko) 2012-04-10
ZA200509752B (en) 2006-11-29
KR101169261B1 (ko) 2012-08-03
MXPA05011752A (es) 2006-06-06
RU2005137569A (ru) 2006-06-10
CN1831119A (zh) 2006-09-13
CA2526670A1 (en) 2004-11-18
JP2006525806A (ja) 2006-11-16
AU2004237749A1 (en) 2004-11-18
RU2006103574A (ru) 2007-08-20
KR101224375B1 (ko) 2013-01-21
RU2345780C2 (ru) 2009-02-10
MXPA05011750A (es) 2006-06-06
KR20060008968A (ko) 2006-01-27
AU2004237749B2 (en) 2011-09-15
CN1831119B (zh) 2010-05-26

Similar Documents

Publication Publication Date Title
WO2004098499A3 (en) Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
Gasparini et al. Transplanted human cones incorporate into the retina and function in a murine cone degeneration model
Magatti et al. The immunomodulatory properties of amniotic cells: the two sides of the coin
KR20140003473A (ko) 양막 유래 부착성 세포를 사용한, 척수 손상 및 외상성 뇌 손상의 치료
Pianta et al. Amniotic mesenchymal cells from pre‐eclamptic placentae maintain immunomodulatory features as healthy controls
Lee et al. Comparison of growth and differentiation of fetal and adult rhesus monkey mesenchymal stem cells
Merola et al. Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expression
JP2014507390A (ja) 胎盤幹細胞を用いる脊髄損傷及び外傷性脳損傷の治療
US8524283B2 (en) T cell immunomodulation by placenta cell preparations
Rocco et al. Regulatory T cells: the ultimate HIV reservoir?
Pereira et al. Human articular chondrocytes regulate immune response by affecting directly T cell proliferation and indirectly inhibiting monocyte differentiation to professional antigen-presenting cells
CN115551887A (zh) 通用细胞疗法的免疫逃逸机制的调节剂
JP2025028953A (ja) 脳卒中、慢性外傷性脳症、及び外傷性脳損傷を含む脳性低酸素症の治療
WO2008063564A3 (en) Isolated myeloid-like cell populations and methods of treatment therewith
Atmaca-Sonmez et al. Systemically transferred hematopoietic stem cells home to the subretinal space and express RPE-65 in a mouse model of retinal pigment epithelium damage
RU2007135220A (ru) Способ лечения ретинопатии при недоношенности и родственных ретинопатических заболеваний
Pérez-Hernández et al. Mitochondrial signature in human monocytes and resistance to infection in C. elegans during fumarate-induced innate immune training
Santa Cruz-Pavlovich et al. Beyond vision: an overview of regenerative medicine and its current applications in ophthalmological care
Plebani et al. Establishment and long-term culture of human cystic fibrosis endothelial cells
CN107206028A (zh) 使用祖细胞治疗眼部病症
MXPA05011752A (es) Celulas madre hematopoyeticas y metodos de tratamiento de enfermedades oculares neovasculares con las mismas.
WO2006031467A3 (en) Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
Sachinidis et al. Investigating the role of T-bet+ B cells (ABCs/DN) in the immunopathogenesis of systemic lupus erythematosus
Souza et al. Efficacy of mesenchymal stem cell‐based therapy on the bone repair of hypertensive rats
WO2006104609A3 (en) Isolated myeloid-like bone marrow cell populations and methods of treatment therewith

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051125

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/06 20060101AFI20070124BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070205

17Q First examination report despatched

Effective date: 20070702

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20101115